Wednesday, ABIVAX Société Anonyme (ABVX) announced the pricing of an underwritten public offering of 6.4 million American Depositary Shares or ADSs, each representing one ordinary share, 0.01 nominal value per share, of the company, for $125 per ADS.
The company has granted underwriters an option to purchase upto an additional 960,000 ADSs on or before the closing of the offering, which is scheduled on July 6, 2026.
The offering is expected to raise approximately $800 million, which will be utilized for expenses related to the potential commercialization of its lead drug candidate, obefazimod, in the United States; and clinical research and development expenses, primarily related to ulcerative colitis and Crohn's disease.
In the pre-market hours, ABVX is trading at $136.99, up 2.80 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Economic News
What parts of the world are seeing the best (and worst) economic performances lately? Click here to check out our Econ Scorecard and find out! See up-to-the-moment rankings for the best and worst performers in GDP, unemployment rate, inflation and much more.
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.